靶向TOP2A治疗卵巢癌：生物学和临床意义

IF 2.8 4区医学 Q2 ONCOLOGY Current oncology Pub Date : 2024-12-20 DOI:10.3390/curroncol31120594

Fulvio Borella, Stefano Fucina, Ylenia Seminara, Pietro Denti, Domenico Ferraioli, Luca Bertero, Niccolò Gallio, Jessica Cusato, Giorgio Valabrega, Alberto Revelli, Luca Marozio, Stefano Cosma

{"title":"靶向TOP2A治疗卵巢癌：生物学和临床意义","authors":"Fulvio Borella, Stefano Fucina, Ylenia Seminara, Pietro Denti, Domenico Ferraioli, Luca Bertero, Niccolò Gallio, Jessica Cusato, Giorgio Valabrega, Alberto Revelli, Luca Marozio, Stefano Cosma","doi":"10.3390/curroncol31120594","DOIUrl":null,"url":null,"abstract":"The enzyme topoisomerase II alpha (TOP2A) plays a critical role in DNA replication and cell proliferation, making it a promising target for cancer therapy. In epithelial ovarian cancer (EOC), TOP2A overexpression is associated with poor prognosis and resistance to conventional treatments. This review explores the biological functions of TOP2A in EOC and discusses its potential as a therapeutic target. We highlight studies on the mechanisms through which TOP2A contributes to tumor progression and recurrence. Additionally, we evaluate the clinical implications of targeting TOP2A, including the use of TOP2A inhibitors and their combination with novel drugs. We provide a comprehensive overview of the current understanding and future directions for targeting TOP2A in the management of EOC.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"8054-8074"},"PeriodicalIF":2.8000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674396/pdf/","citationCount":"0","resultStr":"{\"title\":\"Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications.\",\"authors\":\"Fulvio Borella, Stefano Fucina, Ylenia Seminara, Pietro Denti, Domenico Ferraioli, Luca Bertero, Niccolò Gallio, Jessica Cusato, Giorgio Valabrega, Alberto Revelli, Luca Marozio, Stefano Cosma\",\"doi\":\"10.3390/curroncol31120594\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The enzyme topoisomerase II alpha (TOP2A) plays a critical role in DNA replication and cell proliferation, making it a promising target for cancer therapy. In epithelial ovarian cancer (EOC), TOP2A overexpression is associated with poor prognosis and resistance to conventional treatments. This review explores the biological functions of TOP2A in EOC and discusses its potential as a therapeutic target. We highlight studies on the mechanisms through which TOP2A contributes to tumor progression and recurrence. Additionally, we evaluate the clinical implications of targeting TOP2A, including the use of TOP2A inhibitors and their combination with novel drugs. We provide a comprehensive overview of the current understanding and future directions for targeting TOP2A in the management of EOC.\",\"PeriodicalId\":11012,\"journal\":{\"name\":\"Current oncology\",\"volume\":\"31 12\",\"pages\":\"8054-8074\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-12-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674396/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/curroncol31120594\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol31120594","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

拓扑异构酶II α (TOP2A)在DNA复制和细胞增殖中起着关键作用，使其成为癌症治疗的一个有希望的靶点。在上皮性卵巢癌（EOC）中，TOP2A过表达与预后不良和对常规治疗的耐药性相关。本文综述了TOP2A在EOC中的生物学功能，并讨论了其作为治疗靶点的潜力。我们重点研究了TOP2A促进肿瘤进展和复发的机制。此外，我们评估了靶向TOP2A的临床意义，包括TOP2A抑制剂的使用及其与新药的联合。我们全面概述了在EOC管理中针对TOP2A的当前理解和未来方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications.

The enzyme topoisomerase II alpha (TOP2A) plays a critical role in DNA replication and cell proliferation, making it a promising target for cancer therapy. In epithelial ovarian cancer (EOC), TOP2A overexpression is associated with poor prognosis and resistance to conventional treatments. This review explores the biological functions of TOP2A in EOC and discusses its potential as a therapeutic target. We highlight studies on the mechanisms through which TOP2A contributes to tumor progression and recurrence. Additionally, we evaluate the clinical implications of targeting TOP2A, including the use of TOP2A inhibitors and their combination with novel drugs. We provide a comprehensive overview of the current understanding and future directions for targeting TOP2A in the management of EOC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current oncology ONCOLOGY-

CiteScore

3.30

自引率

7.70%

发文量

664

审稿时长

1 months

期刊介绍： Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.